drugset / Trial / NCT00123149
Open-Label Extension Safety Study of PROCRIT in Patients With Anemia of Chronic Disease Due to Rheumatoid Arthritis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the long-term safety profile of epoetin alfa in patients with anemia of chronic disease due to rheumatoid arthritis
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2007-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | epoetin alfa | Protein / enzyme biologic | 40000 iu | Subcutaneous |
| Subject | epoetin alfa | Protein / enzyme biologic | 60000 iu | Subcutaneous |